GLP-1 Daily: Ozempic & Wegovy News

Wegovy Joins Every Medicare Drug Plan for 2027, With Prior Authorization Attached

Monday, November 16, 2026 · 7 min

GLP-1 Daily: Ozempic & Wegovy News cover art

Medicare's negotiated semaglutide price puts Wegovy on all 5,492 Part D plans for 2027, though not for weight loss alone. Plus European contraception advice for tirzepatide users and Novo Nordisk-funded phase 3 data on lower-dose CagriSema.

Listen

Listen to the audio episode

Read the episode transcript

Show notes

Medicare's negotiated semaglutide price puts Wegovy on all 5,492 Part D plans for 2027, though not for weight loss alone. Plus European contraception advice for tirzepatide users and Novo Nordisk-funded phase 3 data on lower-dose CagriSema.

In this episode

  1. Wegovy goes from 3% to 100% of Medicare Part D plans in 2027 — Medcostclear
    “For 2027, all 5,492 plans list it: 323 of 323 standalone drug plans and 5,169 of 5,169 Medicare Advantage plans with drug coverage. In both years every plan that lists Wegovy requires prior authorization.”
  2. CHMP backs two insulin aspart biosimilars and issues tirzepatide contraceptive advice — Diabesity Rounds Desk
    “Women using an oral contraceptive are now advised to do one of two things. They can add a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Or they can switch to a non-oral method of contraception.”
  3. Lower CagriSema Doses Beat Placebo; Early Response Matters — Medscape
    “Patients with overweight or obesity who received lower doses of the investigational drug CagriSema (Novo Nordisk) — 1.7 mg /1.7 mg and 1.0 mg/1.0 mg instead of the 2.4 mg/2.4 mg used in previous trials of the drug — had an estimated average weight loss of more than 20% for both…”